Literature DB >> 10467383

The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force.

J S Fischer1, R A Rudick, G R Cutter, S C Reingold.   

Abstract

Clinical outcome assessment in Multiple Sclerosis (MS) is challenging due to the diversity and fluctuating nature of MS symptoms. Traditional clinical scales such as the EDSS are inadequate in their assessment of key clinical dimensions of MS (e.g. , cognitive function), and they have psychometric limitations as well. Based on analyses of pooled data from natural history studies and from placebo groups in clinical trials, the National MS Society's Clinical Outcomes Assessment Task Force recently proposed a new multidimensional clinical outcome measure, the MS Functional Composite (MSFC). The MSFC comprises quantitative functional measures of three key clinical dimensions of MS: leg function/ambulation, arm/hand function, and cognitive function. Scores on component measures are converted to standard scores (z-scores), which are averaged to form a single MSFC score. Preliminary analyses confirm that: (1) the three clinical dimensions of the MSFC are relatively independent; (2) the MSFC is sensitive to clinical changes over 1- and 2-year intervals; and (3) the MSFC has acceptable criterion validity (i.e., predicts both concurrent and subsequent EDSS change). The advantages and potential limitations of incorporating quantitative functional outcome measures such as the MSFC into collaborative databases are discussed.

Entities:  

Mesh:

Year:  1999        PMID: 10467383     DOI: 10.1177/135245859900500409

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  278 in total

1.  Compensatory cortical activation observed by fMRI during a cognitive task at the earliest stage of MS.

Authors:  Bertrand Audoin; Danielle Ibarrola; Jean-Philippe Ranjeva; Sylviane Confort-Gouny; Irina Malikova; André Ali-Chérif; Jean Pelletier; Patrick Cozzone
Journal:  Hum Brain Mapp       Date:  2003-10       Impact factor: 5.038

Review 2.  Evaluation of therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser; Ali Fatemi; Kathleen Zackowski; Seth Smith; Xavier Golay; Larry Muenz; Gerald Raymond
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

3.  Magnetic resonance study of the influence of tissue damage and cortical reorganization on PASAT performance at the earliest stage of multiple sclerosis.

Authors:  Bertrand Audoin; My Van Au Duong; Jean-Philippe Ranjeva; Danielle Ibarrola; Irina Malikova; Sylviane Confort-Gouny; Elisabeth Soulier; Patrick Viout; André Ali-Chérif; Jean Pelletier; Patrick J Cozzone
Journal:  Hum Brain Mapp       Date:  2005-03       Impact factor: 5.038

4.  Brain volume and diffusion markers as predictors of disability and short-term disease evolution in multiple sclerosis.

Authors:  P G Sämann; M Knop; E Golgor; S Messler; M Czisch; F Weber
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-01       Impact factor: 3.825

5.  Motor cortical reorganization is present after a single attack of multiple sclerosis devoid of cortico-spinal dysfunction.

Authors:  Audrey Rico; Wafaa Zaaraoui; Jerome Franques; Shahram Attarian; Françoise Reuter; Irina Malikova; Sylviane Confort-Gouny; Elisabeth Soulier; Jean Pouget; Patrick J Cozzone; Jean Pelletier; Jean-Philippe Ranjeva; Bertrand Audoin
Journal:  MAGMA       Date:  2010-12-17       Impact factor: 2.310

6.  Walking function in clinical monitoring of multiple sclerosis by telemedicine.

Authors:  Núria Sola-Valls; Yolanda Blanco; Maria Sepúlveda; Sara Llufriu; Elena H Martínez-Lapiscina; Delon La Puma; Francesc Graus; Pablo Villoslada; Albert Saiz
Journal:  J Neurol       Date:  2015-05-10       Impact factor: 4.849

7.  Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study.

Authors:  J M Stankiewicz; M Neema; D C Alsop; B C Healy; A Arora; G J Buckle; T Chitnis; C R G Guttmann; D Hackney; R Bakshi
Journal:  J Neurol Sci       Date:  2009-04-15       Impact factor: 3.181

8.  Visual search as a tool for a quick and reliable assessment of cognitive functions in patients with multiple sclerosis.

Authors:  Kathrin S Utz; Thomas M A Hankeln; Lena Jung; Alexandra Lämmer; Anne Waschbisch; De-Hyung Lee; Ralf A Linker; Thomas Schenk
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

9.  Validity of the Verbal Concept Attainment Test in multiple sclerosis.

Authors:  Ryan Mulligan; Michael R Basso; Lily Lau; Bradley Reynolds; Douglas M Whiteside; Dennis Combs; Robert A Bornstein
Journal:  J Clin Exp Neuropsychol       Date:  2019-01-14       Impact factor: 2.475

10.  Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.

Authors:  Richard K Burt; Roumen Balabanov; Joachim Burman; Basil Sharrack; John A Snowden; Maria Carolina Oliveira; Jan Fagius; John Rose; Flavia Nelson; Amilton Antunes Barreira; Kristina Carlson; Xiaoqiang Han; Daniela Moraes; Amy Morgan; Kathleen Quigley; Kimberly Yaung; Regan Buckley; Carri Alldredge; Allison Clendenan; Michelle A Calvario; Jacquelyn Henry; Borko Jovanovic; Irene B Helenowski
Journal:  JAMA       Date:  2019-01-15       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.